280E Removal: $350M Unlock and the MSO Index Re-Rate

280E Removal Is a $350 Million Unlock. The Index Funds Are Next.

Where Things Stand

The DEA closed its hearing record on August 17. We covered the briefs in our last piece: the agency asked its own judge to move fast on Schedule III, and the opposition's experts gave the case away on the stand. Marijuana Moment broke the filings. A recommendation this fall is now a live scenario, which turns a policy story into a money story. So let's do the money.

Section 280E has taxed plant-touching operators on gross profit instead of net income for decades. The April order pulled the state-licensed medical channel out from under it. The rule now in front of the tribunal would finish the job for adult-use. Meanwhile, for the first time, a major U.S. multi-state operator qualifies for mainstream index inclusion. Passive money doesn't have opinions about cannabis. It buys what's in the benchmark.

What 280E Removal Is Worth

It won't touch EBITDA. Cost of goods was always deductible, so gross margins and adjusted EBITDA margins don't move an inch. The money shows up below the line. Operating expenses become deductible, cash taxes drop, and net income and free cash flow jump. Across the five largest U.S. operators, our estimates put the recurring benefit north of $350 million a year.

Trulieve leads. On $1.18 billion of FY2025 revenue and 30% adjusted EBITDA margins, we estimate $100 to $140 million a year, or 8 to 12% of revenue. Green Thumb runs similar revenue and margins and screens at $70 to $100 million. It's the cleanest case in the group because it already books real accounting profits.

Curaleaf is a scale story. Thinner margins, but $1.3 billion of revenue gets you $90 to $130 million of benefit. Verano is the one nobody talks about: its $70 to $100 million range works out to 9 to 12% of an $822 million revenue base, the fattest percentage leverage in the group next to Trulieve. Cresco brings up the rear at $35 to $55 million. Smaller dollars, still real money against its debt load.

One wrinkle most models miss. The April order already covers medical, so the medical-heavy operators are banking part of their benefit right now. Trulieve's Florida medical engine is the clearest example; a chunk of its range is de-risked today. Verano and Cresco skew adult-use and need the broader rule to collect. Same catalyst, different odds.

The Re-Rating Math

Don't model this as EBITDA. Run it as free cash flow: adjusted EBITDA, minus interest, minus a normal corporate tax, minus capex. A company doing $300 million of EBITDA and burning $100 million a year in excess 280E taxes doesn't become a $400 million EBITDA company when the rule dies. It becomes a company with $100 million of fresh cash for debt paydown, reinvestment or shareholders. Put a 10x free-cash-flow multiple on that and you're staring at a billion dollars of enterprise value that currently exists only on the government's ledger. That's the re-rate. Same operations, finally keeping their own profit, valued at a normal multiple.

Only One Name Is Buyable

Index eligibility needs two things: a primary NYSE or Nasdaq listing and a U.S. nationality determination. Trulieve $TRLV has both. It listed on the NYSE June 10 and finished its move from British Columbia to Delaware on August 11. Green Thumb, Curaleaf, Verano and Cresco still trade OTC with Canadian primary listings. Doesn't matter how good the numbers are; the index can't hold them. Right now the tax thesis and the index thesis stack in exactly one ticker.

The flow math on that ticker: $1.9 billion market cap, insider stock haircut under Russell's float rules, call it a 4 basis point Russell 2000 weight. Set that against the $250 to $350 billion in passive assets tracking the index and you get $110 to $145 million of forced buying. Fourteen to fifteen million shares. Eight to nine percent of the real float. None of it discretionary.

When the Buying Starts

The calendar is public. Under FTSE Russell's reconstitution schedule, eligibility gets assessed on rank day, the last business day of October: Friday, October 30. Changes go effective after the close on Friday, December 11 and show up in the index Monday morning, December 14. If the June template holds, preliminary add lists post about three weeks after rank day, around November 20, with weekly updates into December.

The index funds themselves buy in the December 11 closing auction. The trade starts earlier. Arb desks model additions off rank day and build positions from the prelim list, and for an add this obvious, some will front it before Halloween. Late October through December 11 is the window, with the mechanical crescendo at the final close. If the ALJ's recommendation drops in the same stretch, the fundamental catalyst lands on top of the flow.

The Sleeper Funds

Russell is the sure thing, but it's not the only door the NYSE listing opened. A handful of broad-market index families kept MSOs out for one mechanical reason: no major U.S. exchange listing. That reason is gone.

The S&P Total Market Index feeds iShares' ITOT and State Street's SPTM. MSCI's USA Small Cap and USA IMI feed iShares products and institutional mandates, and MSCI membership puts a name in front of global allocators for the first time. Dow Jones' U.S. Broad Market family feeds Schwab's SCHB. Vanguard's CRSP US Total Market, the index under VTI, rebalances quarterly and could move before Russell does. No single one of these matches a Russell 2000 add for concentrated flow. Together, they put cannabis inside every total-market portfolio in the country.

The big sleeper is the S&P SmallCap 600, tracked by $SPSM and $IJR, which carries far more passive money per constituent than the Russell 2000. The bar is higher: positive GAAP earnings in the latest quarter and across the trailing four, plus a committee vote. Call it a 2027 story. But watch the loop. 280E relief is what makes GAAP profits stick, and GAAP profits are the ticket into the 600. The tax catalyst builds the next index catalyst.

Two caveats, because we respect the tape. Nobody has tested whether the S&P, $MSCI and $CRSP committees will actually seat a plant-touching operator. The old exclusion was mechanical, but Trulieve is the first case and the final rescheduling call could color it. And the four OTC names aren't locked out forever. Trulieve proved the NYSE will list plant-touchers. Every peer that uplists restarts this same clock for itself.

Bottom Line

280E removal is a free-cash-flow event worth $350 million-plus a year across the top five operators, and free cash flow is what markets pay for. Cash flow needs buyers, and the buyer base now includes index funds with no opinion on cannabis at all. One operator sits at the intersection today, with a published calendar running from an October 30 rank day to the December 11 close. Behind it sit a bench of sleeper index families and an uplist pipeline. This isn't a single-name event. It's the sector getting wired into the ordinary machinery of American capital markets. The gravy train is dying. The flow train just left the station.